Coverage
-
May 19, 2026
As the pharmaceutical industry grapples with the U.S. Supreme Court's refusal to hear about the legality of Medicare drug pricing negotiations, experts say to expect a pivot in and outside the courtrooms.
2 other articles on this case.
View all »